Literature DB >> 20877540

A Second Case of Sunitinib-associated Pyoderma Gangrenosum.

Steven M Dean1, Matthew Zirwas.   

Abstract

Pyoderma gangrenosum is a painful, noninfectious, ulcerative, cutaneous disorder that most commonly affects the lower extremities. The diagnosis is made by recognizing the characteristic clinical manifestations in the setting of a causative systemic disease and excluding other causes of similar-appearing ulcerations. Pyoderma gangrenosum often evolves in the setting of systemic illnesses, such as inflammatory bowel disease, rheumatological disorders, and hematological conditions. However, several medications have rarely been linked to pyoderma gangrenosum. The authors report the second case of sunitinib-associated pyoderma gangrenosum in a 61-year-old patient with recurrent renal cell carcinoma.

Entities:  

Year:  2010        PMID: 20877540      PMCID: PMC2945863     

Source DB:  PubMed          Journal:  J Clin Aesthet Dermatol        ISSN: 1941-2789


  12 in total

1.  ANCA positive propylthiouracil induced pyoderma gangrenosum.

Authors:  K Gungor; S Gonen; G Kisakol; O Dikbas; A Kaya
Journal:  J Endocrinol Invest       Date:  2006-06       Impact factor: 4.256

2.  Adverse reactions to gefitinib (Iressa): revealing sycosis- and pyoderma gangrenosum-like lesions.

Authors:  Rei Sagara; Amane Kitami; Tokio Nakada; Masafumi Iijima
Journal:  Int J Dermatol       Date:  2006-08       Impact factor: 2.736

3.  Pyoderma gangrenosum: another cutaneous side-effect of sunitinib?

Authors:  K ten Freyhaus; B Homey; T Bieber; D Wilsmann-Theis
Journal:  Br J Dermatol       Date:  2008-07-01       Impact factor: 9.302

4.  Expression of c-kit ligand in human keratinocytes.

Authors:  E Morita; D G Lee; M Sugiyama; S Yamamoto
Journal:  Arch Dermatol Res       Date:  1994       Impact factor: 3.017

5.  Granulomatous and suppurative dermatitis at interferon alfa injection sites: report of 2 cases.

Authors:  Scott Sanders; Klaus Busam; Steven R Tahan; Richard A Johnson; Dana Sachs
Journal:  J Am Acad Dermatol       Date:  2002-04       Impact factor: 11.527

6.  Imatinib-induced acute generalized exanthematous pustulosis (AGEP) in two patients with chronic myeloid leukemia.

Authors:  Michaela Schwarz; Karl-Anton Kreuzer; Gökben Baskaynak; Bernd Dörken; Philipp le Coutre
Journal:  Eur J Haematol       Date:  2002-10       Impact factor: 2.997

7.  Imatinib-induced sweet syndrome in a patient with chronic myeloid leukemia.

Authors:  Sanjay J Ayirookuzhi; Li Ma; Priya Ramshesh; Glenn Mills
Journal:  Arch Dermatol       Date:  2005-03

8.  Bullous pyoderma gangrenosum after granulocyte colony-stimulating factor treatment.

Authors:  H J Ross; L A Moy; R Kaplan; R A Figlin
Journal:  Cancer       Date:  1991-07-15       Impact factor: 6.860

9.  Pyoderma gangrenosum related to a new granulocyte colony-stimulating factor.

Authors:  Lucile E White; Mark T Villa; Vesna Petronic-Rosic; Jinxing Jiang; Maria M Medenica
Journal:  Skinmed       Date:  2006 Mar-Apr

10.  Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib.

Authors:  W J Lee; J L Lee; S E Chang; M W Lee; Y K Kang; J H Choi; K C Moon; J K Koh
Journal:  Br J Dermatol       Date:  2009-05-05       Impact factor: 9.302

View more
  3 in total

1.  Spontaneous reporting of serious cutaneous reactions with protein kinase inhibitors.

Authors:  Emmanuelle Faye; Emmanuelle Bondon-Guitton; Pascale Olivier-Abbal; Jean-Louis Montastruc
Journal:  Eur J Clin Pharmacol       Date:  2013-06-09       Impact factor: 2.953

2.  Sunitinib induced pyoderma gangrenosum-like ulcerations.

Authors:  S Akanay-Diesel; N P Hoff; S Kürle; J Haes; A Erhardt; D Häussinger; K-W Schulte; Edwin Bölke; C Matuschek; W Budach; P A Gerber; B Homey
Journal:  Eur J Med Res       Date:  2011-11-10       Impact factor: 2.175

3.  Leech Induced Pyoderma Gangrenosum in an Ulcerative Colitis Patient: A Case Report.

Authors:  Anahita Sadeghi; Behrouz Navabakhsh; Niloofar Izadi Vahedi
Journal:  Middle East J Dig Dis       Date:  2016-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.